Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Lung01 in EGFR-mutated NSCLC after failure of third-generation EGFR TKI therapy
NL-OMON60521Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoints: Recommended phase 3 dose and Progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60521.